Why Cell Line Screening is Crucial for CDC Bioassay Development
In recent years, one of the major improvements in oncotherapy has been the development of monoclonal antibodies (mAbs) targeting tumor-specific antigens. The ability of these antibodies to kill tumor cells is largely dependent on their Fc effector function. While the complementarity-determining region (CDR) of the molecule binds the specific tumor antigen, the Fc portion induces target-cell killing by three main mechanisms: complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). In this application note, we outline a new tool for the development of a CDC assay for mAb biological characterization and QC release testing.